{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:59:44Z","timestamp":1790272784178,"version":"4.1.0"},"reference-count":22,"publisher":"Baishideng Publishing Group Inc.","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Hepatol"],"abstract":"<jats:p>Primary sclerosing cholangitis (PSC) is a chronic and progressive immune-mediated cholangiopathy causing biliary tree inflammation and scarring, leading to liver cirrhosis and end-stage liver disease. Diagnosis of PSC is challenging due to its nonspecific symptoms and overlap with other liver diseases. Despite the rising incidence of PSC, there is no proven medical therapy that can alter the natural history of the disease. While liver transplantation (LT) is the most effective approach for managing advanced liver disease caused by PSC, post-transplantation recurrence of PSC remains a challenge. Therefore, ongoing research aims to develop better therapies for PSC, and continued efforts are necessary to improve outcomes for patients with PSC. This article provides an overview of PSC\u2019s pathogenesis, clinical presentation, and management options, including LT trends and future aspects. It also highlights the need for improved therapeutic options and ethical considerations in providing equitable access to LT for patients with PSC. Additionally, the impact of liver transplant on the quality of life and psychological outcomes of patients with PSC is discussed. Ongoing research into PSC\u2019s pathogenesis and post-transplant recurrence is crucial for improved understanding of the disease and more effective treatment options. <\/jats:p>","DOI":"10.4254\/wjh.v15.i8.973","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:31:24Z","timestamp":1692671484000},"page":"973-984","source":"Crossref","is-referenced-by-count":2,"title":["Stages of care for patients with chronic hepatitis C at a hospital in southern Brazil"],"prefix":"10.4254","volume":"15","author":[{"given":"Manoela Badinelli","family":"Vaucher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Ubirajara","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana Ros\u00e2ngela Santos","family":"Varella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Yu-Shin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas Alexandre","family":"Kliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"key":"B1","unstructured":"World Health Organization.   Global Health Sector Strategy on Viral Hepatitis, 2016\u20132021: towards ending viral hepatitis. April 26, 2018. [cited 1 June 2023]. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf"},{"key":"B2","unstructured":"World Health Organization.   Global Hepatitis Report 2017. 2017. [cited 1 June 2023]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789241565455"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz714"},{"key":"B4","unstructured":"World Health Organization.   Global reporting system for hepatitis (GRSH)\u2013project description. 2018. [cited 1 June 2023]. Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hepatitis\/strategic-information\/global-reporting-system"},{"key":"B5","unstructured":"World Health Organization.   Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries. March 2018. [cited 1 June 2023]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/260445\/WHO-CDS-HIV-18.4-eng.pdf?sequence=1"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-04962-3"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12512"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101554"},{"key":"B9","unstructured":"Brazil Ministry of Health.   Secretary of Health Surveillance. Prevention and Control of Sexually Transmitted Infections, HIV\/AIDS and Viral Hepatitis. Plan for the Elimination of Hepatitis C in Brazil. Bras\u00edlia: Ministry of Health, 2018. [cited 1 June 2023]. Available from: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/protocolo_clinico_hiv_sifilis_hepatites.pdf"},{"key":"B10","unstructured":"Coalition for Global Hepatitis Elimination.   Perfil Nacional De Elimina\u00e7\u00e3o. Das Hepatites Virais. Julho, 2021. [cited 1 June 2023]. Available from: https:\/\/www.globalhep.org\/sites\/default\/files\/content\/news\/files\/2021-07\/National%20Hepatitis%20Elimination%20Profile_Brazil_July%2028.pdf"},{"key":"B11","unstructured":"BRAZIL.   Ministry of Health. Secretary of Health Surveillance. Department of Surveillance, Prevention and Control of STIs, HIV\/AIDS and Viral Hepatitis. Epidemiological Bulletin of Viral Hepatitis. Brasilia: Ministry of Health, 2022. [cited 1 June 2023]. Available from: https:\/\/www.gov.br\/saude\/pt-br\/centrais-de-conteudo\/publicacoes\/boletins\/epidemiologicos\/especiais\/2022\/boletim-epidemiologico-de-hepatites-virais-2022-numero-especial"},{"key":"B12","unstructured":"Grupo Hospitalar Concei\u00e7\u00e3o.   Letter of Services to the Citizen. 2017. [cited 1 June 2023]. Available from: https:\/\/www.ghc.com.br\/files\/cartacidadao.pdf."},{"key":"B13","unstructured":"Government of the State of Rio Grande do Sul.   State Health Surveillance Center. Epidemiological Bulletin Viral Hepatitis, Rio Grande do Sul. July, 2022. [cited 1 June 2023]. Available from: https:\/\/saude.rs.gov.br\/upload\/arquivos\/202207\/25120953-boletim-epidemiologico-hepatites-virais-2022.pdf"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.051"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00397-6"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07271-z"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.880435"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2020-001521"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1713657"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-021-01470-7"},{"key":"B21","unstructured":"Luetkemeyer AF, Wyles DL. CROI 2019: highlights of viral hepatitis. Top Antivir Med 2019; 27: 41-49"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258143"}],"container-title":["World Journal of Hepatology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v15\/i8\/973.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v15\/i8\/973.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:31:40Z","timestamp":1692671500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v15\/i8\/973.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":22,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.4254\/wjh.v15.i8.973","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,27]]}}}